![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2024
Fischer, Luca 
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
2021
Schmitz, Norbert; Truemper, Lorenz; Bouabdallah, Krimo; Ziepert, Marita; Leclerc, Mathieu; Cartron, Guillaume; Jaccard, Arnaud; Reimer, Peter; Wagner, Eva; Wilhelm, Martin; Sanhes, Laurence; Lamy, Thierry; de Leval, Laurence; Rosenwald, Andreas; Roussel, Muriel; Kroschinsky, Frank; Lindemann, Walter; Dreger, Peter; Viardot, Andreas; Milpied, Noeel; Gisselbrecht, Christian; Wulf, Gerald; Gyan, Emmanuel; Gaulard, Philippe; Bay, Jacques Olivier; Glass, Bertram; Poeschel, Viola; Damaj, Gandhi; Sibon, David; Delmer, Alain; Bilger, Karin; Banos, Anne; Haenel, Mathias; Dreyling, Martin; Metzner, Bernd; Keller, Ulrich; Braulke, Friederike; Friedrichs, Birte; Nickelsen, Maike; Altmann, Bettina und Tournilhac, Olivier
(2021):
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
In: Blood, Bd. 137, Nr. 19: S. 2646-2656
2020
Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Dimou, Maria; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Munoz, Javier; Rodrigues, Liana; Hiemeyer, Florian; Miriyala, Ashok; Garcia‐Vargas, Jose; Childs, Barrett H. und Zinzani, Pier Luigi
(2020):
Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study.
In: American Journal of Hematology, Bd. 95, Nr. 4: S. 362-371
[PDF, 1MB]
2017
Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George A.; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Panayiotidis, Panayiotis; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Giurescu, Marius; Cupit, Lisa; Liu, Li; Köchert, Karl; Seidel, Henrik; Pena, Carol; Yin, Shuxin; Hiemeyer, Florian; Garcia-Vargas, Jose; Childs, Barrett H. und Zinzani, Pier Luigi
(2017):
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
In: Journal of Clinical Oncology, Bd. 35, Nr. 35: S. 3898-3910